Getinge launches Fluobeam LS and expands fluorescence imaging for minimally invasive procedures

Getinge announces the launch of Fluobeam LS, expanding its portfolio for fluorescence imaging in minimally invasive surgery. The system has been developed for procedures such as thyroid surgeries and sentinel lymph node (SLN) detection in breast cancer. It helps surgeons identify anatomical structures that are difficult to distinguish by providing real-time visualization, thereby supporting intraoperative decision-making.

Fluobeam LS was developed based on many years of clinical experience and feedback from surgeons. The system builds on the strengths of previous generations while addressing challenges related to accessibility and visibility in minimally invasive procedures. By leveraging the established expertise of Fluoptics in fluorescence imaging, the system combines precision, ergonomic design, and efficient workflows to support minimally invasive surgical interventions.

"We are committed to innovations that help surgeons achieve the best possible outcomes for their patients," says Stéphane Le Roy, President of Surgical Workflows at Getinge. "Fluobeam LS is the result of close collaboration with surgical teams and addresses specific clinical requirements. The versatile platform supports multiple indications and creates additional value for hospitals."

With its compact and lightweight design, Fluobeam LS integrates seamlessly into the operating room. The ergonomically designed optical camera head can be positioned close to the surgical field without impairing visibility. An integrated joystick allows intuitive control of imaging functions. High-resolution imaging combined with quantitative assessment tools provides objective information during critical phases of the procedure. Special modes enable use across different indications.

These features support key procedural steps in the system’s main clinical applications:

– Thyroid Surgery: Identifying and preserving the parathyroid glands is crucial to avoid complications such as postoperative hypocalcemia. Fluobeam LS uses fluorescence imaging to enable better tissue differentiation and assist surgeons in more accurately assessing the blood flow to the parathyroid glands.
– Breast Cancer Surgery: Precise detection of sentinel lymph nodes is essential but can be limited by conventional methods. Fluobeam LS allows clear visualization of lymphatic pathways—even through small incisions—and supports accurate detection and more efficient surgical workflows.

By contributing to the optimization of patient care, Fluobeam LS offers both clinical and economic benefits for healthcare facilities.

"We continuously expand our expertise in fluorescence imaging to support efficient and high-quality care," says Olivier Pacaud, Managing Director of Fluorescence Imaging at Getinge. "With its intuitive design and reliable performance, Fluobeam LS helps hospitals use resources efficiently, simplify surgical workflows, and strengthen collaboration among clinical teams."

Fluobeam LS was introduced at the European Society of Endocrine Surgeons Congress in Geneva in May 2026, highlighting the increasing adoption of fluorescence-guided procedures in minimally invasive surgery. The system has CE marking and will be commercially available in European markets.